This short video from MuscleOwl shares the facts about the FDA’s approval of Spinraza (nusinersen). The approval is great news for the SMA community and gives patients and parents renewed hope for the future.
The efficacy of Spinraza in a phase 3 clinical trial has taken the world by storm with 40 percent of participants showing major improvement. Infants with the most severe kind of spinal muscular atrophy reported meeting development milestones such as crawling, head control, standing and even walking–milestones that would have been impossible without the drug.
The FDA has approved the drug for babies, children and adults.
SMA News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.